Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance

Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular pharmaceutics 2021-06, Vol.18 (6), p.2218-2232
Hauptverfasser: Qiu, Yingshan, Clarke, Maria, Wan, Leon T. L, Lo, Jason C. K, Mason, A. James, Lam, Jenny K. W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2232
container_issue 6
container_start_page 2218
container_title Molecular pharmaceutics
container_volume 18
creator Qiu, Yingshan
Clarke, Maria
Wan, Leon T. L
Lo, Jason C. K
Mason, A. James
Lam, Jenny K. W
description Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly­(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration.
doi_str_mv 10.1021/acs.molpharmaceut.0c01242
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2531229065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2531229065</sourcerecordid><originalsourceid>FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EgvL4BWR2bFL8LlkiKKWiggrBhk3k2BM1KImDnRSVr8dVSyV2rDyyz1zPHIQuKBlSwuiVNmFYu6pdaF9rA303JIZQJtgeGlApeHLNU7a_q6_FEToO4YMQJiTjh-iIC0KFUnKA3p_brqzLb92VrsGuwPPxZFXpDix-nAk8h_hsARfO41C-PN3gO6jKJfgV_iq7BZ7WrXfLCM_7qnaNjvevrgKvGwOn6KDQVYCz7XmC3u7Hr7cPyex5Mr29mSWaK94laa4tTwUBC8IoSjRVkmoriQKl7UiJvDBEp7kRsshHRhdWFTYlOeGRpEbxE3S5yY2jfPYQuqwug4Gq0g24PmRMcspYSpSMaLpBjXcheCiy1pd1nDqjJFurzaLa7I_abKs29p5vv-nzGuyu89dlBOQGWGd8uN43cet_BP8AG0iOJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2531229065</pqid></control><display><type>article</type><title>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Qiu, Yingshan ; Clarke, Maria ; Wan, Leon T. L ; Lo, Jason C. K ; Mason, A. James ; Lam, Jenny K. W</creator><creatorcontrib>Qiu, Yingshan ; Clarke, Maria ; Wan, Leon T. L ; Lo, Jason C. K ; Mason, A. James ; Lam, Jenny K. W</creatorcontrib><description>Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly­(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.0c01242</identifier><identifier>PMID: 34014665</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>A549 Cells ; Drug Carriers - chemistry ; Gene Silencing ; Humans ; Hydrophobic and Hydrophilic Interactions ; Lung - metabolism ; Peptides - chemistry ; Polyethylene Glycols - chemistry ; Respiratory Tract Diseases - genetics ; Respiratory Tract Diseases - therapy ; RNA, Small Interfering - administration &amp; dosage ; RNA, Small Interfering - genetics ; Solubility ; Transfection - methods</subject><ispartof>Molecular pharmaceutics, 2021-06, Vol.18 (6), p.2218-2232</ispartof><rights>2021 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</citedby><cites>FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</cites><orcidid>0000-0003-4129-4810 ; 0000-0003-0411-602X ; 0000-0003-2997-010X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.0c01242$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c01242$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>315,781,785,2766,27078,27926,27927,56740,56790</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34014665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qiu, Yingshan</creatorcontrib><creatorcontrib>Clarke, Maria</creatorcontrib><creatorcontrib>Wan, Leon T. L</creatorcontrib><creatorcontrib>Lo, Jason C. K</creatorcontrib><creatorcontrib>Mason, A. James</creatorcontrib><creatorcontrib>Lam, Jenny K. W</creatorcontrib><title>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly­(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration.</description><subject>A549 Cells</subject><subject>Drug Carriers - chemistry</subject><subject>Gene Silencing</subject><subject>Humans</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Lung - metabolism</subject><subject>Peptides - chemistry</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Respiratory Tract Diseases - genetics</subject><subject>Respiratory Tract Diseases - therapy</subject><subject>RNA, Small Interfering - administration &amp; dosage</subject><subject>RNA, Small Interfering - genetics</subject><subject>Solubility</subject><subject>Transfection - methods</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtOwzAQRS0EgvL4BWR2bFL8LlkiKKWiggrBhk3k2BM1KImDnRSVr8dVSyV2rDyyz1zPHIQuKBlSwuiVNmFYu6pdaF9rA303JIZQJtgeGlApeHLNU7a_q6_FEToO4YMQJiTjh-iIC0KFUnKA3p_brqzLb92VrsGuwPPxZFXpDix-nAk8h_hsARfO41C-PN3gO6jKJfgV_iq7BZ7WrXfLCM_7qnaNjvevrgKvGwOn6KDQVYCz7XmC3u7Hr7cPyex5Mr29mSWaK94laa4tTwUBC8IoSjRVkmoriQKl7UiJvDBEp7kRsshHRhdWFTYlOeGRpEbxE3S5yY2jfPYQuqwug4Gq0g24PmRMcspYSpSMaLpBjXcheCiy1pd1nDqjJFurzaLa7I_abKs29p5vv-nzGuyu89dlBOQGWGd8uN43cet_BP8AG0iOJg</recordid><startdate>20210607</startdate><enddate>20210607</enddate><creator>Qiu, Yingshan</creator><creator>Clarke, Maria</creator><creator>Wan, Leon T. L</creator><creator>Lo, Jason C. K</creator><creator>Mason, A. James</creator><creator>Lam, Jenny K. W</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4129-4810</orcidid><orcidid>https://orcid.org/0000-0003-0411-602X</orcidid><orcidid>https://orcid.org/0000-0003-2997-010X</orcidid></search><sort><creationdate>20210607</creationdate><title>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</title><author>Qiu, Yingshan ; Clarke, Maria ; Wan, Leon T. L ; Lo, Jason C. K ; Mason, A. James ; Lam, Jenny K. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a363t-9bad3940ede4c610a1651ad506e6ad764bfc0a9bc45fb7cafd6fd90b03a161c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>A549 Cells</topic><topic>Drug Carriers - chemistry</topic><topic>Gene Silencing</topic><topic>Humans</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Lung - metabolism</topic><topic>Peptides - chemistry</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Respiratory Tract Diseases - genetics</topic><topic>Respiratory Tract Diseases - therapy</topic><topic>RNA, Small Interfering - administration &amp; dosage</topic><topic>RNA, Small Interfering - genetics</topic><topic>Solubility</topic><topic>Transfection - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qiu, Yingshan</creatorcontrib><creatorcontrib>Clarke, Maria</creatorcontrib><creatorcontrib>Wan, Leon T. L</creatorcontrib><creatorcontrib>Lo, Jason C. K</creatorcontrib><creatorcontrib>Mason, A. James</creatorcontrib><creatorcontrib>Lam, Jenny K. W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qiu, Yingshan</au><au>Clarke, Maria</au><au>Wan, Leon T. L</au><au>Lo, Jason C. K</au><au>Mason, A. James</au><au>Lam, Jenny K. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2021-06-07</date><risdate>2021</risdate><volume>18</volume><issue>6</issue><spage>2218</spage><epage>2232</epage><pages>2218-2232</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly­(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>34014665</pmid><doi>10.1021/acs.molpharmaceut.0c01242</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-4129-4810</orcidid><orcidid>https://orcid.org/0000-0003-0411-602X</orcidid><orcidid>https://orcid.org/0000-0003-2997-010X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1543-8384
ispartof Molecular pharmaceutics, 2021-06, Vol.18 (6), p.2218-2232
issn 1543-8384
1543-8392
language eng
recordid cdi_proquest_miscellaneous_2531229065
source MEDLINE; American Chemical Society Journals
subjects A549 Cells
Drug Carriers - chemistry
Gene Silencing
Humans
Hydrophobic and Hydrophilic Interactions
Lung - metabolism
Peptides - chemistry
Polyethylene Glycols - chemistry
Respiratory Tract Diseases - genetics
Respiratory Tract Diseases - therapy
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - genetics
Solubility
Transfection - methods
title Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T08%3A38%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20PEGylated%20KL4%20Peptide%20for%20siRNA%20Delivery%20with%20Improved%20Pulmonary%20Tolerance&rft.jtitle=Molecular%20pharmaceutics&rft.au=Qiu,%20Yingshan&rft.date=2021-06-07&rft.volume=18&rft.issue=6&rft.spage=2218&rft.epage=2232&rft.pages=2218-2232&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.0c01242&rft_dat=%3Cproquest_cross%3E2531229065%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2531229065&rft_id=info:pmid/34014665&rfr_iscdi=true